Acute Lymphoblastic Leukemia

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

201 drugs in development·38 companies·46 clinical trials

Drug Pipeline by Phase

Phase 3(91)
DrugCompany
asciminibGH Research PLC (GHRS)
Asparaginase Erwinia chrysanthemiAssertio Holdings, Inc. (ASRT)
Asparaginase Erwinia chrysanthemiCosmos Health Inc. (COSM)
AZD0486ASTRAZENECA PLC (AZN)
Bleomycin SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabCosmos Health Inc. (COSM)
BlinatumomabAXIM BIOTECHNOLOGIES, INC. (AXIM)
BlinatumomabCrinetics Pharmaceuticals, Inc. (CRNX)
CalaspargaseFilana Therapeutics Inc. (FLNA)
Calaspargase PegolFilana Therapeutics Inc. (FLNA)
Calaspargase PegolMerus N.V. (MRUS)
Calaspargase PegolAssertio Holdings, Inc. (ASRT)
Calaspargase PegolCosmos Health Inc. (COSM)
Calaspargase PegolAXIM BIOTECHNOLOGIES, INC. (AXIM)
CAR-TFilana Therapeutics Inc. (FLNA)
CD22 CAR-transduced T cellsFilana Therapeutics Inc. (FLNA)
chemotherapy agentsTAKEDA PHARMACEUTICAL CO LTD (TKPHF)
ClofarabineMerus N.V. (MRUS)
ctl019Novartis AG (NVS)
CTL019Novartis AG (NVS)
CytarabineCosmos Health Inc. (COSM)
CytarabineAssertio Holdings, Inc. (ASRT)
CytarabineAXIM BIOTECHNOLOGIES, INC. (AXIM)
CytarabineCrinetics Pharmaceuticals, Inc. (CRNX)
DasatinibCrinetics Pharmaceuticals, Inc. (CRNX)
DasatinibAssertio Holdings, Inc. (ASRT)
DasatinibCosmos Health Inc. (COSM)
DasatinibAXIM BIOTECHNOLOGIES, INC. (AXIM)
DaunorubicinCosmos Health Inc. (COSM)
DaunorubicinAssertio Holdings, Inc. (ASRT)
Daunorubicin HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Daunorubicin HydrochlorideAssertio Holdings, Inc. (ASRT)
Dexrazoxane HydrochlorideAssertio Holdings, Inc. (ASRT)
Gemtuzumab OzogamicinAssertio Holdings, Inc. (ASRT)
HydrocortisoneAssertio Holdings, Inc. (ASRT)
HydrocortisoneMerus N.V. (MRUS)
Hydrocortisone Sodium SuccinateAssertio Holdings, Inc. (ASRT)
hypercvadAMGEN INC (AMGN)
idarubicinGH Research PLC (GHRS)
IfosfamideAssertio Holdings, Inc. (ASRT)
ImatinibCosmos Health Inc. (COSM)
Imatinib MesylateAssertio Holdings, Inc. (ASRT)
Imatinib MesylateFilana Therapeutics Inc. (FLNA)
induction phaseGH Research PLC (GHRS)
inotuzumabGH Research PLC (GHRS)
InotuzumabENANTA PHARMACEUTICALS INC (ENTA)
Inotuzumab ozogamicinAssertio Holdings, Inc. (ASRT)
Inotuzumab OzogamicinAXIM BIOTECHNOLOGIES, INC. (AXIM)
Inotuzumab OzogamicinFilana Therapeutics Inc. (FLNA)
IsatuximabSanofi (SNY)
kte-c19Kite Pharma, Inc. (KITE)
LeucovorinCosmos Health Inc. (COSM)
LeucovorinAXIM BIOTECHNOLOGIES, INC. (AXIM)
Leucovorin CalciumAXIM BIOTECHNOLOGIES, INC. (AXIM)
Leucovorin CalciumCosmos Health Inc. (COSM)
LevoleucovorinAssertio Holdings, Inc. (ASRT)
Liposome-encapsulated Daunorubicin-CytarabineAssertio Holdings, Inc. (ASRT)
low-intensity chemotherapy regimenAMGEN INC (AMGN)
maintenanceGH Research PLC (GHRS)
MercaptopurineAssertio Holdings, Inc. (ASRT)
MercaptopurineENANTA PHARMACEUTICALS INC (ENTA)
MercaptopurineCosmos Health Inc. (COSM)
Mercaptopurine Oral SuspensionCosmos Health Inc. (COSM)
Mercaptopurine Oral SuspensionAssertio Holdings, Inc. (ASRT)
MesnaAssertio Holdings, Inc. (ASRT)
MesnaAXIM BIOTECHNOLOGIES, INC. (AXIM)
MesnaMerus N.V. (MRUS)
MesnaCrinetics Pharmaceuticals, Inc. (CRNX)
Mitoxantrone HydrochlorideAssertio Holdings, Inc. (ASRT)
OfatumumabENANTA PHARMACEUTICALS INC (ENTA)
PegaspargaseENANTA PHARMACEUTICALS INC (ENTA)
PegaspargaseMerus N.V. (MRUS)
PegaspargaseCosmos Health Inc. (COSM)
PegaspargaseAXIM BIOTECHNOLOGIES, INC. (AXIM)
PonatinibENANTA PHARMACEUTICALS INC (ENTA)
Ponatinib HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Ponatinib HydrochlorideCrinetics Pharmaceuticals, Inc. (CRNX)
Procarbazine HydrochlorideAXIM BIOTECHNOLOGIES, INC. (AXIM)
Selumetinib SulfateMerus N.V. (MRUS)
Therapeutic HydrocortisoneAssertio Holdings, Inc. (ASRT)
ThioguanineENANTA PHARMACEUTICALS INC (ENTA)
ThioguanineAssertio Holdings, Inc. (ASRT)
ThioguanineCosmos Health Inc. (COSM)
ThioguanineMerus N.V. (MRUS)
Vinblastine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
VincristineAXIM BIOTECHNOLOGIES, INC. (AXIM)
VincristineCosmos Health Inc. (COSM)
Vincristine SulfateAXIM BIOTECHNOLOGIES, INC. (AXIM)
Vincristine SulfateCosmos Health Inc. (COSM)
Vincristine SulfateAssertio Holdings, Inc. (ASRT)
Vincristine SulfateCrinetics Pharmaceuticals, Inc. (CRNX)
Phase 2(70)
DrugCompany
6-MercaptopurineAssertio Holdings, Inc. (ASRT)
AcetaminophenAssertio Holdings, Inc. (ASRT)
AcetaminophenENANTA PHARMACEUTICALS INC (ENTA)
AcetaminophenMerus N.V. (MRUS)
Asparaginase Erwinia chrysanthemiAXIM BIOTECHNOLOGIES, INC. (AXIM)
atgGH Research PLC (GHRS)
AUCATZYL/obe-celAutolus Therapeutics plc (AUTL)
BlinatumomabMerus N.V. (MRUS)
BortezomibStructure Therapeutics Inc. (GPCR)
CalaspargaseAssertio Holdings, Inc. (ASRT)
cd19+GH Research PLC (GHRS)
cd45ra-depleted dliGH Research PLC (GHRS)
Cetuximab Sarotalocan SodiumMerus N.V. (MRUS)
CLLS52Cellectis S.A. (CLLS)
ClofarabineStructure Therapeutics Inc. (GPCR)
ClofarabineENANTA PHARMACEUTICALS INC (ENTA)
cnct19CASI Pharmaceuticals, Inc (DE) (CASI)
CytarabineARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CytarabinePROTHENA CORP PUBLIC LTD CO (PRTA)
CytarabineCidara Therapeutics, Inc. (CDTX)
DasatinibMerus N.V. (MRUS)
DiphenhydramineCidara Therapeutics, Inc. (CDTX)
DiphenhydramineMerus N.V. (MRUS)
DiphenhydramineENANTA PHARMACEUTICALS INC (ENTA)
DiphenhydramineAssertio Holdings, Inc. (ASRT)
DiphenhydraminePROTHENA CORP PUBLIC LTD CO (PRTA)
EtoposideStructure Therapeutics Inc. (GPCR)
FilgrastimFilana Therapeutics Inc. (FLNA)
filgrastim or equivalentSanofi (SNY)
fludarabineSanofi (SNY)
fludarabineHWH International Inc. (HWH)
g-csfGH Research PLC (GHRS)
HydrocortisoneENANTA PHARMACEUTICALS INC (ENTA)
HydrocortisoneARROWHEAD PHARMACEUTICALS, INC. (ARWR)
HydrocortisoneCidara Therapeutics, Inc. (CDTX)
HydrocortisonePROTHENA CORP PUBLIC LTD CO (PRTA)
HydrocortisoneStructure Therapeutics Inc. (GPCR)
idarubicinSanofi (SNY)
InotuzumabAssertio Holdings, Inc. (ASRT)
Inotuzumab ozogamicinPROTHENA CORP PUBLIC LTD CO (PRTA)
Inotuzumab ozogamicinARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Inotuzumab ozogamicinCidara Therapeutics, Inc. (CDTX)
Inotuzumab ozogamicinENANTA PHARMACEUTICALS INC (ENTA)
Inotuzumab ozogamicinStructure Therapeutics Inc. (GPCR)
isatuximabSanofi (SNY)
l - asparaginaseSanofi (SNY)
l - asparginaseSanofi (SNY)
liposomal daunorubicinSanofi (SNY)
mb-cart19.1CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
mercaptopurineMerus N.V. (MRUS)
mitoxantroneSanofi (SNY)
Obe-cel (AUTO1)Autolus Therapeutics plc (AUTL)
OfatumumabFilana Therapeutics Inc. (FLNA)
OfatumumabStructure Therapeutics Inc. (GPCR)
OfatumumabMerus N.V. (MRUS)
pegaspargase asparaginaseSanofi (SNY)
PegfilgrastimFilana Therapeutics Inc. (FLNA)
PonatinibFilana Therapeutics Inc. (FLNA)
post-remissionGH Research PLC (GHRS)
post-transplant abataceptGH Research PLC (GHRS)
post-transplant tacrolimusGH Research PLC (GHRS)
re-induction phaseGH Research PLC (GHRS)
Sodium ThiosulfateMerus N.V. (MRUS)
tcrα/β+GH Research PLC (GHRS)
UCART22Cellectis S.A. (CLLS)
Vinblastine SulfateMerus N.V. (MRUS)
vincristineMerus N.V. (MRUS)
vincristineSanofi (SNY)
Vincristine SulfateMerus N.V. (MRUS)
Vincristine Sulfate LiposomeStructure Therapeutics Inc. (GPCR)

Compare drugs

Frequently asked questions

How many drugs are in development for Acute Lymphoblastic Leukemia?

BioSniper tracks 201 drugs in development for Acute Lymphoblastic Leukemia across 38 companies.

How many clinical trials target Acute Lymphoblastic Leukemia?

There are 46 clinical trials targeting Acute Lymphoblastic Leukemia tracked by BioSniper.

What is the prevalence of Acute Lymphoblastic Leukemia?

The estimated prevalence of Acute Lymphoblastic Leukemia is approximately 8.0 per 100,000 population.

Deep-dive into Acute Lymphoblastic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis